MA49884A - Composés imidazo[4,5-c]quinolin-2-one deutérés et leur utilisation dans le traitement du cancer - Google Patents

Composés imidazo[4,5-c]quinolin-2-one deutérés et leur utilisation dans le traitement du cancer

Info

Publication number
MA49884A
MA49884A MA049884A MA49884A MA49884A MA 49884 A MA49884 A MA 49884A MA 049884 A MA049884 A MA 049884A MA 49884 A MA49884 A MA 49884A MA 49884 A MA49884 A MA 49884A
Authority
MA
Morocco
Prior art keywords
deuterates
quinolin
imidazo
cancer
treatment
Prior art date
Application number
MA049884A
Other languages
English (en)
Inventor
Bernard Christophe Barlaam
Kurt Gordon Pike
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MA49884A publication Critical patent/MA49884A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA049884A 2017-03-16 2018-03-15 Composés imidazo[4,5-c]quinolin-2-one deutérés et leur utilisation dans le traitement du cancer MA49884A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762472080P 2017-03-16 2017-03-16

Publications (1)

Publication Number Publication Date
MA49884A true MA49884A (fr) 2020-06-24

Family

ID=61801891

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049884A MA49884A (fr) 2017-03-16 2018-03-15 Composés imidazo[4,5-c]quinolin-2-one deutérés et leur utilisation dans le traitement du cancer

Country Status (25)

Country Link
US (2) US20200087300A1 (fr)
EP (1) EP3596076A1 (fr)
JP (1) JP2020514344A (fr)
KR (1) KR20190129923A (fr)
CN (1) CN110431139B (fr)
AU (1) AU2018234985B2 (fr)
BR (1) BR112019018723A2 (fr)
CA (1) CA3055258A1 (fr)
CL (1) CL2019002527A1 (fr)
CO (1) CO2019010029A2 (fr)
CR (1) CR20190429A (fr)
DO (1) DOP2019000228A (fr)
EA (1) EA038233B1 (fr)
EC (1) ECSP19066134A (fr)
IL (1) IL269272A (fr)
JO (1) JOP20190209A1 (fr)
MA (1) MA49884A (fr)
MX (1) MX2019010898A (fr)
NI (1) NI201900094A (fr)
PE (1) PE20191486A1 (fr)
PH (1) PH12019502086A1 (fr)
SG (1) SG11201908065YA (fr)
TW (1) TW201843151A (fr)
UA (1) UA124554C2 (fr)
WO (1) WO2018167203A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LV15575A (lv) * 2019-12-20 2021-06-20 Latvijas Organiskās Sintēzes Institūts Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana
JP2023539715A (ja) 2020-06-24 2023-09-19 アストラゼネカ ユーケー リミテッド 抗体－薬物コンジュゲートとａｔｍ阻害剤との組合わせ
EP4142710B1 (fr) * 2020-09-21 2024-01-31 Wei Zhong Composés substitués de 1-(3,3-difluoropipéridin-4-yl)-imidazo[4,5-c]quinoléin-2-one présentant une aptitude à traverser la barrière hémato-encéphalique
EP3992191A1 (fr) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Dérivés d'imidazo[4,5-c]quinoline et leur utilisation en tant qu'inhibiteurs de kinase atm
WO2022128833A1 (fr) 2020-12-15 2022-06-23 Merck Patent Gmbh Complexes métal-ligand de transition solide

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
CN1116286C (zh) 1996-03-05 2003-07-30 曾尼卡有限公司 4－苯胺基喹唑啉衍生物
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US20090082387A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
MX2011012943A (es) * 2009-06-04 2012-01-27 Novartis Ag Derivados de 1h-imidazo-[4,5-c]-quinolinona.
CN102372711B (zh) 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
NO2714752T3 (fr) * 2014-05-08 2018-04-21
EP3560924B1 (fr) * 2015-04-02 2021-03-31 Merck Patent GmbH Imidazolonyl-quinoléines et leur utilisation comme inhibiteurs du atm kinase
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer

Also Published As

Publication number Publication date
PE20191486A1 (es) 2019-10-18
CL2019002527A1 (es) 2019-11-22
CN110431139B (zh) 2022-07-05
EA201992090A1 (ru) 2020-03-06
WO2018167203A1 (fr) 2018-09-20
IL269272A (en) 2019-11-28
TW201843151A (zh) 2018-12-16
EA038233B1 (ru) 2021-07-28
BR112019018723A2 (pt) 2020-04-07
AU2018234985A1 (en) 2019-10-24
AU2018234985B2 (en) 2020-04-02
EP3596076A1 (fr) 2020-01-22
CR20190429A (es) 2019-11-12
ECSP19066134A (es) 2019-09-30
JOP20190209A1 (ar) 2019-09-12
PH12019502086A1 (en) 2020-03-09
NI201900094A (es) 2020-03-18
CA3055258A1 (fr) 2018-09-20
CN110431139A (zh) 2019-11-08
US20200087300A1 (en) 2020-03-19
JP2020514344A (ja) 2020-05-21
UA124554C2 (uk) 2021-10-05
SG11201908065YA (en) 2019-09-27
CO2019010029A2 (es) 2019-09-30
MX2019010898A (es) 2019-11-07
DOP2019000228A (es) 2019-09-30
KR20190129923A (ko) 2019-11-20
US20210347775A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
MA39960A (fr) Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer
MA52886A (fr) Composés de purinone et leur utilisation dans le traitement du cancer
MA49884A (fr) Composés imidazo[4,5-c]quinolin-2-one deutérés et leur utilisation dans le traitement du cancer
FR22C1011I2 (fr) Promedicaments de fumarates et leur utilisation pour le traitement de diverses maladies
MA49458A (fr) Composés interagissant avec la superfamille ras destinés à être utilisés dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques
IL258818A (en) Imidazo[4,5-c]quinolin-2-ion compounds and their use in cancer treatment
MA45122A (fr) Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
HK1257677A1 (zh) 咪唑並[4，5-c]喹啉-2-酮化合物以及它們在治療癌症中的用途
MA46085A (fr) Dérivés d'imidazole et leur utilisation dans le traitement de maladies ou de cancers auto-immuns ou inflammatoires
GB201517215D0 (en) Use of cannabinoids in the treatment of inflammatory skin diseases
MA47450A (fr) Sulfinylpyridines et leur utilisation dans le traitement du cancer
GB201516504D0 (en) Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201608227D0 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
IL284125A (en) History of quinoline for use in the treatment of inflammatory diseases
MA42915A (fr) Pyridines et leur utilisation dans le traitement du cancer
MA43767A (fr) Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancer
MA47811A (fr) Kit comprenant un conjugué anticorps-médicament igf-1r et son utilisation pour le traitement du cancer
MA44762A (fr) Sémaglutide utilisé dans le traitement de maladies cardiovasculaires
ZA201804950B (en) Indolinones compounds and their use in the treatment of fibrotic diseases
GB201604182D0 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
MA47451A (fr) Pyridines à substitution hétéroarylsulfonyle et leur utilisation dans le traitement du cancer
IL266128B (en) History of naphthyridinone and its use in the treatment of arrhythmia
MA39912B1 (fr) Dérivés de 2-aryl-4-hydroxy-1,3-thiazole comme antagonistes du trpm8, et leur utilisation dans le traitement de la neuralgie, de la douleur, de la bpco et de l'asthme.
MA43250A (fr) Composés d'oxadiazaspiro pour le traitement de l'abus et la dépendance aux drogues